News Lilly trumpets heart health data with Mounjaro Eli Lilly has raised the stakes in its rivalry with Novo Nordisk on GLP-1 drugs for diabetes, with new data for Mounjaro on cardiovascular outcomes.
News UK authority cracks down on weight-loss drug ads Nine adverts for weight-loss services have been banned by the Advertising Standards Authority in the UK for promoting prescription-only drugs.
News UK probes link between GLP-1 drugs and pancreatitis The UK is studying cases of pancreatitis in people taking GLP-1 drugs for weight loss or type 2 diabetes to see if genetics may make them vulnerable.
News ADA: Lilly makes its case for oral GLP-1 orforglipron Lilly is on track to file its oral GLP-1 agonist orforglipron for type 2 diabetes next year after presenting the first phase 3 data with the drug.
News Could a Novo error set up early GLP-1 generics in Canada? Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
News MHRA advises contraception for women taking 'skinny jabs' Women in the UK taking weight-loss injections have been warned by the MHRA that they should make sure they are using effective contraception.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.